Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262243 | 0.85 | BRD4 (0.33) | BRD4ALDH1A1KMT2APOLB | |
| SCHEMBL8302482 | 0.84 | KDR (0.34) | SMN1; SMN2NPC1TP53TSHRKMT2A | |
| SCHEMBL5265326 | 0.83 | NPC1 (0.32) | SMN1; SMN2NPC1TP53TSHRL3MBTL1 | |
| SCHEMBL5230010 | 0.74 | PDE4A (0.36) | KMT2AL3MBTL1LMNAKDR | |
| SCHEMBL6100048 | 0.74 | PDE4A (0.37) | SMN1; SMN2NPC1TP53TSHRALDH1A1 | |
| SCHEMBL5886505 | 0.74 | NPC1 (0.36) | BRD4SMN1; SMN2NPC1TP53TSHR | |
| SCHEMBL4763289 | 0.73 | NPC1 (0.32) | BRD4SMN1; SMN2NPC1TP53TSHR | |
| SCHEMBL8306194 | 0.72 | KDR (0.35) | SMN1; SMN2NPC1TP53TSHRALDH1A1 | |
| SCHEMBL5266946 | 0.71 | PDE1A (0.31) | BRD4 | |
| SCHEMBL4767966 | 0.69 | PDE10A (0.34) | SMN1; SMN2NPC1TP53TSHRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619948-A4 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | NEUROGEN CORPORATION | 2006-11-02 | — | — | US | claimed |
| EP-1619948-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-02-01 | — | — | EP | claimed |
| WO-2004107863-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-12-16 | — | — | WO | claimed |
| EP-1619948-A4 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | NEUROGEN CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1619948-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004107863-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004107863-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | GABRA5, GABRA3, GABRA2 | BRD4 1899/4885SMN1; SMN2 985/4885NPC1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.